Anticoagulation for atrial fibrillation in patients on dialysis: Are the benefits worth the risks?

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 6, 2012, Pages 600-606

  Shen, Jenny I ^a   Turakhia, Mintu P ^a   Winkelmayer, Wolfgang C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atrial fibrillation; end stage renal disease; hemorrhage; mortality; stroke

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BELGIUM; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DIALYSIS; DRUG INDICATION; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; JAPAN; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; INTRACRANIAL HEMORRHAGES; KIDNEY FAILURE, CHRONIC; PHYSICIAN'S PRACTICE PATTERNS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84868223127     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835856fd     Document Type: Review

References (51)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention-the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.
2. Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 2012; 5:85-93.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
4. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290:1049-1056.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457.
6. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870.
7. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297-305.
8. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354.
9. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011; 4:26-32.
10. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2011; 123:2946-2953.
11. Winkelmayer WC, Patrick AR, Liu J, et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011; 22:349-357.
12. Wetmore JB, Mahnken JD, Rigler SK, et al. The prevalence of and factors associated with chronic atrial fibrillation inMedicare/Medicaid-eligible dialysis patients. Kidney Int 2012; 81:469-476.
13. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77:1098-1106.
14. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20:2223-2233.
15. Goldstein BA, Turakhia M, Arce CM, Winkelmayer WC. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. 49th European Renal Association-European Dialysis and Transplant Association Congress. Paris, France; 2012.
16. Winkelmayer WC, Liu J, Patrick AR, et al. Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. J Nephrol 2012; 25:341-353.
17. Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007; 167:246-252.
18. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006; 97:538-543.
19. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005; 21:1583-1594.
20. Herzog CA, Solid CA. Atrial fibrillation and stroke in the general Medicare population: a fifteen year perspective (1992-2007) [abstract]. Circulation 2011; 124:A8293.
21. Seliger SL, Gillen DL, Longstreth WT Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64:603-609.
22. Seliger SL, Gillen DL, Tirschwell D, et al. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 2003; 14:2623-2631.
23. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; 76:324-330.
24. Boyle JM, Johnston B. Acute upper gastrointestinal hemorrhage in patients with chronic renal disease. Am J Med 1983; 75:409-412.
25. Yang JY, Lee TC, Montez-Rath ME, et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 2012; 23:495-506.
26. Elseviers MM, Van Waeleghem JP. Identifying vascular access complications among ESRD patients in Europe. A prospective, multicenter study. Nephrol News Issues 2003; 17:61-64; 66-68, 99.
27. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20:872-881.
28. Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis 2012; 60:473-486.
29. Bennett WM. Should dialysis patients ever receive warfarin and for what reasons? Clin J Am Soc Nephrol 2006; 1:1357-1359.
30. HorlWH.Coumarin use in dialysis patients with atrial [corrected] fibrillation: yes, after individual risk stratification. Nephrol Dial Transplant 2009; 24:3285-3287.
31. Holden RM, Sanfilippo AS, Hopman WM, et al. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol 2007; 20:417-422.
32. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32:384-391.
33. Wiesholzer M, Harm F, Tomasec G, et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 2001; 21:35-39.
34. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 2003; 4:1.
35. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46:897-902.
36. Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis 2009; 2:33-37.
37. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011; 6:2662-2668.
38. Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128:513-519.
39. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975-983.
40. Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost: JTH 2010; 8:2182-2191.
41. Yang F, Xu X, Winkelmayer WC, et al. Warfarin use and bleeding risk in veterans with incident atrial fibrillation and severe chronic kidney disease: the TREAT-AF Study [abstract]. Heart Rhythm 2012; 9:S2922012.
42. Turakhia MP. Quality of stroke prevention care in atrial fibrillation: many moving targets. Circ Cardiovasc Qual Outcomes 2011; 4:5-8.
43. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
44. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
45. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
46. European Medicines Agency Updates on Safety of Pradaxa (Press Release). http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/11/ WC500117818.pdf. [Accessed 6 December 2011]
47. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Dabigatran (Pradaxa): risk of bleeding relating to use. http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm. [Accessed 7 December 2011]
48. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Dabigatran (Pradaxa) & the risk of bleeding: new recommendations for monitoring kidney function. http://www.tga.gov.au/safety/ alertsmedicine-dabigatran-111103.htm. [Accessed 7 December 2011]
49. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47:285-295.
50. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32:2387-2394.
51. Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis 2007; 50:421-432.